Rubius Therapeutics, Inc. (RUBY) |
| 0.057 0.002 (2.7%) 12-29 15:49 |
| Open: | 0.0555 |
| High: | 0.057 |
| Low: | 0.055 |
| Volume: | 755,858 |
| Market Cap: | 0(M) |
| PE Ratio: | -0.03 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.03 |
| Resistance 1: | 0.02 |
| Pivot price: | 0.02 |
| Support 1: | 0.01 |
| Support 2: | 0.01 |
| 52w High: | 0.3763 |
| 52w Low: | 0.0032 |
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Financials
| EPS | -2.080 |
| Book Value | 0.170 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -46.6 |
| Return on Equity (ttm) | -185.3 |
Company news
Wed, 22 Feb 2023
Once high-flying Rubius to shut down. Its flameout is a lesson for biotech - statnews.com
Wed, 22 Feb 2023
Rubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternatives - Yahoo Finance
Thu, 09 Feb 2023
Fmr Cuts Stake in Rubius Therapeutics (RUBY) - Nasdaq
Thu, 17 Nov 2022
Former Rubius CEO jumps to another Flagship spinout - The Business Journals
Tue, 13 Sep 2022
Rubius Therapeutics Announces Strategic Update - Yahoo Finance
Fri, 05 Aug 2022
Frank Zhang returns to Legend - biocentury.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
